Yougant Airan
Yougant Airan has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Seth B. Herzon
Yale University
2 shared publications Collin Heer
Department of Therapeutic Radiology
1 shared publication- Daniel R. Semlow
Division of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, USA
1 shared publication Elliot J. MacKrell
Division of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, USA
1 shared publication- Emily P. Balskus
Harvard University
1 shared publication Jennifer A. Roth
Broad Institute of MIT and Harvard
1 shared publication
Latest Publications
- 19 December 2025
- Published by American Chemical Society (ACS) in ACS Chemical Biology
- Vol. 21 (1) , 26-36
Synthesis and Biological Evaluation of Colibactin Derivatives
Colibactin is a pseudo-C2-symmetric gut microbiome metabolite that induces DNA interstrand cross-links and plays a causal role in colorectal cancer. Since efforts to isolate colibactin have not been successful, we developed colibactin 742 (3a/b) as a stable colibactin mimetic. However, colibactin 742 (3a/b) exists as a mixture of ring and chain isomers, which complicates analysis of its activity. We report here the discovery of colibactin 686 (9) as a superior colibactin mimetic. Colibactin 686 (9) is more potent than colibactin 742 (3a/b) and recapitulates the bacterial genotoxic phenotype. Colibactin 686 (9) possesses a C2-symmetric structure, which will expedite its synthesis, and is incapable of ring-chain isomerization, which will simplify analysis of its biological activity. We additionally establish that colibactins do not passively diffuse into cells, and are substrates for monocarboxylate transporter pumps. These latter findings have implications for trafficking of natural colibactin, which remains poorly understood.
- 19 December 2025
- Published by American Chemical Society (ACS) in ACS Chemical Biology
- Vol. 21 (1) , 26-36
Synthesis and Biological Evaluation of Colibactin Derivatives
Colibactin is a pseudo-C2-symmetric gut microbiome metabolite that induces DNA interstrand cross-links and plays a causal role in colorectal cancer. Since efforts to isolate colibactin have not been successful, we developed colibactin 742 (3a/b) as a stable colibactin mimetic. However, colibactin 742 (3a/b) exists as a mixture of ring and chain isomers, which complicates analysis of its activity. We report here the discovery of colibactin 686 (9) as a superior colibactin mimetic. Colibactin 686 (9) is more potent than colibactin 742 (3a/b) and recapitulates the bacterial genotoxic phenotype. Colibactin 686 (9) possesses a C2-symmetric structure, which will expedite its synthesis, and is incapable of ring-chain isomerization, which will simplify analysis of its biological activity. We additionally establish that colibactins do not passively diffuse into cells, and are substrates for monocarboxylate transporter pumps. These latter findings have implications for trafficking of natural colibactin, which remains poorly understood.
- Open Access
- 26 November 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 10563
The Fanconi anemia pathway repairs colibactin-induced DNA interstrand cross-links
Colibactin is a secondary metabolite produced by bacteria present in the human gut and is implicated in the development of colorectal cancer. This genotoxin alkylates deoxyadenosines on opposite strands of host cell DNA to produce DNA interstrand cross-links. While cells have evolved multiple mechanisms to resolve (“unhook”) interstrand cross-links, little is known about which of these pathways promote resistance to colibactin. Here, we use Xenopus egg extracts to investigate replication-coupled repair of colibactin-induced interstrand cross-links. We show that replication fork stalling at a colibactin-induced interstrand cross-link activates the Fanconi anemia interstrand cross-link repair pathway, which unhooks the interstrand cross-link through nucleolytic incisions. These incisions generate a DNA double-strand break intermediate in one sister chromatid, which can be repaired by homologous recombination, and a monoadduct (“interstrand cross-link remnant”) in the other. Translesion synthesis past the colibactin-induced interstrand cross-link remnant depends on Pol η and the Pol κ-REV1-Pol ζ polymerase complex and introduces predominantly T>A point mutations at the sites of colibactin alkylation. Taken together, our work provides a molecular framework for understanding how cells tolerate a naturally occurring and clinically relevant interstrand cross-link.
- 26 November 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 10563
Open AccessThe Fanconi anemia pathway repairs colibactin-induced DNA interstrand cross-links
Colibactin is a secondary metabolite produced by bacteria present in the human gut and is implicated in the development of colorectal cancer. This genotoxin alkylates deoxyadenosines on opposite strands of host cell DNA to produce DNA interstrand cross-links. While cells have evolved multiple mechanisms to resolve (“unhook”) interstrand cross-links, little is known about which of these pathways promote resistance to colibactin. Here, we use Xenopus egg extracts to investigate replication-coupled repair of colibactin-induced interstrand cross-links. We show that replication fork stalling at a colibactin-induced interstrand cross-link activates the Fanconi anemia interstrand cross-link repair pathway, which unhooks the interstrand cross-link through nucleolytic incisions. These incisions generate a DNA double-strand break intermediate in one sister chromatid, which can be repaired by homologous recombination, and a monoadduct (“interstrand cross-link remnant”) in the other. Translesion synthesis past the colibactin-induced interstrand cross-link remnant depends on Pol η and the Pol κ-REV1-Pol ζ polymerase complex and introduces predominantly T>A point mutations at the sites of colibactin alkylation. Taken together, our work provides a molecular framework for understanding how cells tolerate a naturally occurring and clinically relevant interstrand cross-link.